Galectin Therapeutics reported $27.29M in Current Assets for its fiscal quarter ending in June of 2024.





Current Assets Change Date
AbbVie USD 33.67B 140M Jun/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Galectin Therapeutics USD 27.29M 1.83M Jun/2024
Gilead Sciences USD 12.53B 6.11B Jun/2026
Immunic USD 188.76M 165.89M Mar/2026
Incyte USD 6.03B 542.31M Jun/2026
Merck USD 35.02B 8.5B Mar/2026